Autres langues 60 Degrees Pharmaceuticals, Inc.

Actions

SXTP

US83006G1040

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,2529 ^USD	-5,85 %		-10,21 %	-75,18 %

27/06	60 Degrees Pharmaceuticals, Inc. annonce le recrutement du premier patient dans l'essai clinique de 60 Degrees Pharmaceuticals sur la tafénoquine pour le traitement de la babésiose au Tufts Medical Center	CI
30/05	60 Degrees Pharmaceuticals, Inc. conclut un accord avec le Tufts Medical Center de Boston pour mener le premier essai clinique de la tafénoquine dans le traitement des patients atteints de babésiose humaine	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind	27/06
60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center	27/06
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis	11/06
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind	30/05
60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients	30/05
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	20/05
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	20/05
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results	15/05
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases	08/05
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	02/05
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	02/05
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis	03/04
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	14/03
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	14/03
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris	20/02
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer	08/02
60 Degrees Pharmaceuticals, Inc. Appoints Kristen Landon as Chief Commercial Officer	08/02
60 Degrees Pharmaceuticals Closes $2.4 Million Public Offering	31/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues 60 Degrees Pharmaceuticals, Inc.

Actions

SXTP

US83006G1040

Autres langues

Filtres